Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis

Created:
December 11, 2020
News organization:
Rocket Pharmaceuticals
News type:
Press release